These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 33866450)

  • 1. PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine.
    Cataldi S; Costa V; Ciccodicola A; Aprile M
    Curr Diab Rep; 2021 Apr; 21(6):18. PubMed ID: 33866450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
    Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
    Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L; Bahij El-Houri R
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances on PPARγ Research in the Emerging Era of Precision Medicine.
    Lu P; Zhao Z
    Curr Drug Targets; 2018; 19(6):663-673. PubMed ID: 28641522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A step ahead of PPARγ full agonists to PPARγ partial agonists: therapeutic perspectives in the management of diabetic insulin resistance.
    Chigurupati S; Dhanaraj SA; Balakumar P
    Eur J Pharmacol; 2015 May; 755():50-7. PubMed ID: 25748601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
    Evans JL; Lin JJ; Goldfine ID
    Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPAR gamma gene--a review.
    Janani C; Ranjitha Kumari BD
    Diabetes Metab Syndr; 2015; 9(1):46-50. PubMed ID: 25450819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential Roles of Post-Translational Modifications of PPARγ in Treating Diabetes.
    Ji X; Zhang W; Yin L; Shi Z; Luan J; Chen L; Liu L
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid metabolism in patients with PPARgamma mutations.
    Tan GD; Savage DB; Fielding BA; Collins J; Hodson L; Humphreys SM; O'Rahilly S; Chatterjee K; Frayn KN; Karpe F
    J Clin Endocrinol Metab; 2008 Nov; 93(11):4462-70. PubMed ID: 18713822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fat Mass Reduction With Adipocyte Hypertrophy and Insulin Resistance in Heterozygous PPARγ Mutant Rats.
    Gumbilai V; Ebihara K; Aizawa-Abe M; Ebihara C; Zhao M; Yamamoto Y; Mashimo T; Hosoda K; Serikawa T; Nakao K
    Diabetes; 2016 Oct; 65(10):2954-65. PubMed ID: 27381370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes.
    Costa V; Federico A; Pollastro C; Ziviello C; Cataldi S; Formisano P; Ciccodicola A
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR(gamma) and glucose homeostasis.
    Picard F; Auwerx J
    Annu Rev Nutr; 2002; 22():167-97. PubMed ID: 12055342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic PPARγ deletion in mice provokes lipoatrophy, organomegaly, severe type 2 diabetes and metabolic inflexibility.
    Gilardi F; Winkler C; Quignodon L; Diserens JG; Toffoli B; Schiffrin M; Sardella C; Preitner F; Desvergne B
    Metabolism; 2019 Jun; 95():8-20. PubMed ID: 30878493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
    Cho N; Momose Y
    Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gallic acid attenuates high-fat diet fed-streptozotocin-induced insulin resistance via partial agonism of PPARγ in experimental type 2 diabetic rats and enhances glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway.
    Gandhi GR; Jothi G; Antony PJ; Balakrishna K; Paulraj MG; Ignacimuthu S; Stalin A; Al-Dhabi NA
    Eur J Pharmacol; 2014 Dec; 745():201-16. PubMed ID: 25445038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice.
    Gray SL; Nora ED; Grosse J; Manieri M; Stoeger T; Medina-Gomez G; Burling K; Wattler S; Russ A; Yeo GS; Chatterjee VK; O'Rahilly S; Voshol PJ; Cinti S; Vidal-Puig A
    Diabetes; 2006 Oct; 55(10):2669-77. PubMed ID: 17003330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of PPARG and LPIN1 gene polymorphisms with metabolic syndrome and type 2 diabetes.
    Bego T; Dujic T; Mlinar B; Semiz S; Malenica M; Prnjavorac B; Ostanek B; Marc J; Causević A
    Med Glas (Zenica); 2011 Feb; 8(1):76-83. PubMed ID: 21263402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism.
    Shafi S; Gupta P; Khatik GL; Gupta J
    Curr Drug Targets; 2019; 20(12):1281-1294. PubMed ID: 31131751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.